Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial

Jun Li; Jingliang Xing; Yefa Yang; Jingfeng Liu; Wentao Wang; Yong Xia; Zhenlin Yan; Kui Wang; Dong Wu; Lu Wu; Xuying Wan; Tian Yang; Chunfang Gao; Anfeng Si; Hongyang Wang; Mengchao Wu; Wan Yee Lau; Zhinan Chen; Feng Shen

doi:10.1016/S2468-1253(19)30422-4

Adjuvant ¹³¹I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial

Lancet Gastroenterol Hepatol. 2020 Jun;5(6):548-560. doi: 10.1016/S2468-1253(19)30422-4. Epub 2020 Mar 9.

Authors

Jun Li¹, Jingliang Xing², Yefa Yang³, Jingfeng Liu⁴, Wentao Wang⁵, Yong Xia¹, Zhenlin Yan¹, Kui Wang¹, Dong Wu¹, Lu Wu³, Xuying Wan⁶, Tian Yang¹, Chunfang Gao⁷, Anfeng Si⁶, Hongyang Wang⁸, Mengchao Wu⁹, Wan Yee Lau¹⁰, Zhinan Chen², Feng Shen¹¹

Affiliations

¹ Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
² Cell Engineering Research Center, Fourth Military Medical University, Xi'an, China.
³ Department of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
⁴ Department of Hepatobiliary Surgery, First Affiliated and Mengchao Hepatobiliary Surgery Hospital, Fujian Medical University, Fuzhou, China.
⁵ Department of Hepatopancreatobiliary Surgery, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
⁶ Department of Clinical Database, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
⁷ Clinical Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
⁸ National Centre for Liver Cancer, Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer of the Ministry of Education of China, Shanghai Key Laboratory of Hepatobiliary Tumor Biology, Second Military Medical University, Shanghai, China.
⁹ Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
¹⁰ Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Faculty of Medicine, Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Area, China.
¹¹ Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Electronic address: shenfengehbh@sina.com.

PMID: 32164877
DOI: 10.1016/S2468-1253(19)30422-4

Abstract

Background: Effective adjuvant treatment after hepatectomy for hepatocellular carcinoma (HCC) is an important area of research. Radioactive iodine (¹³¹I)-labelled metuximab is a radiolabelled monoclonal antibody against the CD147 (also known as basigin or HAb18G) antigen that is expressed in HCC. We aimed to examine the role of ¹³¹I-metuximab as an adjuvant therapy after HCC resection.

Methods: This randomised, controlled, multicentre, open-label, phase 2 trial was done at five medical centres in China. Patients aged 18-75 years who underwent curative-intent resection of histologically confirmed HCC expressing CD147 were randomly assigned (1:1) by a computer-generated random sequence, stratified by centre, to receive either adjuvant transarterial injection of one dose of 27·75 MBq/kg ¹³¹I-metuximab 4-6 weeks after the hepatectomy (treatment group) or no adjuvant treatment (control group). Patients and physicians were not masked to the study groups. The primary outcome was 5-year recurrence-free survival (RFS) in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT00819650.

Findings: Between April 1, 2009, and Nov 30, 2012, 485 patients were screened for eligibility. 329 (68%) of these patients were excluded and 156 (32%) were randomly assigned to receive either ¹³¹I-metuximab (n=78) or no adjuvant treatment (n=78). The median follow-up was 55·9 months (IQR 18·6-79·4). In the intention-to-treat population, the 5-year RFS was 43·4% (95% CI 33·6-55·9) in the ¹³¹I-metuximab group and 21·7% (14·2-33·1) in the control group (hazard ratio 0·49 [95% CI 0·34-0·72]; Z=2·96, p=0·0031). ¹³¹I-metuximab-associated adverse events occurred within the first 4 weeks in 34 (45%) of 76 patients, seven (21%) of whom had grade 3 or 4 adverse events. These adverse events were all resolved with appropriate treatment within 2 weeks of being identified.

Interpretation: Adjuvant ¹³¹I-metuximab treatment significantly improved the 5-year RFS of patients after hepatectomy for HCC tumours expressing CD147. This treatment was well tolerated by patients.

Funding: State Key Project on Infectious Diseases of China.

Publication types

Clinical Trial, Phase II
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Carcinoma, Hepatocellular / pathology
Carcinoma, Hepatocellular / radiotherapy*
Disease-Free Survival
Female
Hepatectomy*
Humans
Iodine Radioisotopes / therapeutic use*
Liver Neoplasms / pathology
Liver Neoplasms / radiotherapy*
Male
Middle Aged
Proportional Hazards Models
Radioimmunotherapy
Radiotherapy, Adjuvant
Treatment Outcome

Substances

Antibodies, Monoclonal
Iodine Radioisotopes
metuximab

Associated data

ClinicalTrials.gov/NCT00819650